CL2022000198A1 - Composición farmacéutica que comprende inhibidores de la hmg-coa·reductasa y fenofibrato - Google Patents

Composición farmacéutica que comprende inhibidores de la hmg-coa·reductasa y fenofibrato

Info

Publication number
CL2022000198A1
CL2022000198A1 CL2022000198A CL2022000198A CL2022000198A1 CL 2022000198 A1 CL2022000198 A1 CL 2022000198A1 CL 2022000198 A CL2022000198 A CL 2022000198A CL 2022000198 A CL2022000198 A CL 2022000198A CL 2022000198 A1 CL2022000198 A1 CL 2022000198A1
Authority
CL
Chile
Prior art keywords
fenofibrate
pharmaceutical composition
hmg
coa reductase
reductase inhibitors
Prior art date
Application number
CL2022000198A
Other languages
English (en)
Inventor
Venkataramana Naidu
Hitendra Netlal Rahangdale
Narendra Bhagwatbhai Prajapati
Satyavan Shivajirao Dhavale
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72266598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2022000198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of CL2022000198A1 publication Critical patent/CL2022000198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica multicapa que comprende una combinación de dosis fija de rosuvastatina o una sal farmacéuticamente aceptable de esta y fenofibrato o una sal farmacéuticamente aceptable de este, donde el fenofibrato o su sal y la rosuvastatina o su sal están presentes en capas separadas, donde el fenofibrato y la rosuvastatina se liberan inmediatamente de sus capas, y donde la capa de fenofibrato comprende fenofibrato micronizado. Proceso para la preparación de dicha composición.
CL2022000198A 2019-07-31 2022-01-25 Composición farmacéutica que comprende inhibidores de la hmg-coa·reductasa y fenofibrato CL2022000198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921030870 2019-07-31
EP19201186 2019-10-02

Publications (1)

Publication Number Publication Date
CL2022000198A1 true CL2022000198A1 (es) 2022-09-23

Family

ID=72266598

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000198A CL2022000198A1 (es) 2019-07-31 2022-01-25 Composición farmacéutica que comprende inhibidores de la hmg-coa·reductasa y fenofibrato

Country Status (14)

Country Link
US (1) US20220273652A1 (es)
EP (2) EP4115879A1 (es)
JP (1) JP2022542004A (es)
CN (1) CN114173786A (es)
AU (1) AU2020320448A1 (es)
BR (1) BR112022001514A2 (es)
CA (1) CA3148035A1 (es)
CL (1) CL2022000198A1 (es)
CO (1) CO2022000808A2 (es)
ES (1) ES2931301T3 (es)
MX (1) MX2022001178A (es)
PL (1) PL3833335T3 (es)
RS (1) RS63740B1 (es)
WO (1) WO2021019493A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114903862B (zh) * 2022-06-15 2023-08-22 湖北中古生物制药有限公司 一种多廿烷醇阿托伐他汀钙复方制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
KR20060085686A (ko) 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
US20050096391A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
MXPA06003813A (es) 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
CN1993111A (zh) * 2004-05-21 2007-07-04 阿库-伯雷克技术公司 含有相对无活性片段的药片
US20080131503A1 (en) 2005-02-10 2008-06-05 Per Holm Stable Pharmaceutical Composition Comprising a Fixed Dose Combination of Fenofibrate and an Hmg-Coa Reductase Inhibitor
WO2008075320A2 (en) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Antilipidemic pharmaceutical compositions and process for preparation thereof
JP2011525901A (ja) 2008-06-27 2011-09-29 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ ロスバスタチンカルシウム含有医薬組成物
US20110311625A1 (en) * 2010-06-14 2011-12-22 Amruth Gowda Doddaveerappa Solid dosage forms of fenofibrate
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
ES2931301T3 (es) 2022-12-28
WO2021019493A1 (en) 2021-02-04
PL3833335T3 (pl) 2023-01-02
AU2020320448A1 (en) 2022-02-17
BR112022001514A2 (pt) 2022-03-22
CN114173786A (zh) 2022-03-11
CA3148035A1 (en) 2021-02-04
EP3833335A1 (en) 2021-06-16
JP2022542004A (ja) 2022-09-29
EP4115879A1 (en) 2023-01-11
CO2022000808A2 (es) 2022-02-07
RS63740B1 (sr) 2022-12-30
EP3833335B1 (en) 2022-08-31
US20220273652A1 (en) 2022-09-01
MX2022001178A (es) 2022-02-22

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CO2021007447A2 (es) Métodos de tratamiento para la fibrosis quística
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CL2022000198A1 (es) Composición farmacéutica que comprende inhibidores de la hmg-coa·reductasa y fenofibrato
AR104257A1 (es) Tableta de ribociclib
UY37941A (es) Derivados de bencimidazol y sus usos
CL2022000725A1 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
AR085132A1 (es) Composiciones farmaceuticas para el tratamiento de glioma maligno
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
CL2015003561A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular.
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina
CL2022003477A1 (es) Compuesto de alquenilpirimidina, método de preparación del mismo y aplicación del mismo
UY38319A (es) Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
AR126251A1 (es) Inhibidores de cdk2
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
CL2008003062A1 (es) Compuestos derivados de pirazoles espiro conjugados, inhibidores de la actividad de ksp kinesina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.